Sandy Hinckley
Vice President, Head of Discovery QurAlis Corp.
Dr. Sandy Hinckley is Head of Biology, Principal Scientist and brings expertise in human stem cell biology and neurodegenerative research to the team. She completed her Ph.D. at the University of Wisconsin-Madison, where she developed an ex vivo gene therapy approach in ALS therapeutics utilizing stem cell model systems for disease relevant cell types. She continued her training at the University of California San Diego in human cortical development by investigating pathways in the generation of corticospinal motor neurons from stem cells. Later she joined the Prebys Center for Drug Discovery, focusing on phenotypic screening in iPSC-derived neurons where she developed assays for mitochondrial and neuronal network function.
Seminars
- Why ALS and FTD demand a discovery first rethink, and how deep integration of genetics, clinical phenotypes, biomarkers, and longitudinal data reveals disease driving biology missed by traditional approaches
- Using human data to drive target identification and prioritisation, grounding ALS & FTD pipelines in patient relevant mechanisms from the outset
- Bridging ALS–FTD biology to inform shared and divergent pathways, and how this insight shapes programme strategy, indication selection, and translational confidence
- Building a scalable discovery engine for neurodegeneration, where integrated platforms accelerate progression from biological insight to pipeline ready therapeutic hypotheses
